Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...

A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...

Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

"Anti-vaccine rhetoric is a threat to global health," said biomedical scientist Andrea C. Love, PhD, emphasizing how ...

A systematic review and meta-analysis of five studies suggested that patients on GLP-1 receptor agonists were more likely to ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

GLP-1 medications initially were used to help people with diabetes improve their insulin resistance and hunger cravings.

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...